CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

Home・Aktien・Ocugen Inc

Ocugen Inc

Geschlossen

1.22 -2.4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.22

Max

1.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -19M
Verkäufe	1.7M 1.5M
EPS	-0.06
Gewinnspanne	-1,250.946
Angestellte	116
EBITDA	-987K -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+807.14% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	31. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-162M 464M
Vorheriger Eröffnungskurs	3.62
Vorheriger Schlusskurs	1.22

Ocugen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Ocugen Inc Prognose

Kursziel

By TipRanks

807.14% Vorteil

12-Monats-Prognose

Durchschnitt 11.43 USD 807.14%

Hoch 22 USD

Tief 7 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocugen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ocugen Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.